Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist Human Methylome Panel, designed to enhance research in cancer metastasis and human development. This innovative panel covers 84.2% of CpG islands and offers significant cost savings compared to traditional methods. The panel allows researchers to identify biologically relevant methylation markers, thereby supporting advanced applications in liquid biopsy technologies. It promises a higher dynamic range for accurate detection of differentially methylated regions, facilitating better diagnostic tests and research assays.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on May 23 at 9:15 a.m. ET in New York. The event will be webcast live, accessible via the company’s Investor Calendar. A replay will be available for 30 days after the live event. Twist Bioscience is a leader in synthetic biology, utilizing innovative DNA synthesis technology to produce synthetic DNA for various applications, including healthcare and drug discovery.
BigHat Biosciences has appointed Rob Chess to its board of directors. With extensive experience in biotech leadership, Chess aims to leverage his expertise in drug discovery to enhance BigHat's mission of developing advanced antibody therapies. He is the former CEO of Nektar Therapeutics (NASDAQ:NKTR) and currently serves as Chairman at Twist Biosciences (NASDAQ:TWST). BigHat, founded in 2019 and based in the San Francisco Bay Area, focuses on innovative therapeutic solutions using AI and has raised $25 million to date, establishing key partnerships with leading biopharma.
Twist Bioscience (NASDAQ: TWST), a leader in synthetic DNA technology, announced that Steffen Hellmold will represent the company at the 2022 Materials Research Society (MRS) Spring Meeting in Honolulu, Hawaii, from May 8-13. Hellmold will participate in the '2030 Decadal Plan for Semiconductors Panel Discussion' on May 12. This panel will explore the anticipated demand for silicon-based memory and potential solutions, including DNA data storage. Twist’s innovative platform focuses on synthesizing high-quality DNA products for various sectors including healthcare and drug discovery.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a research collaboration and exclusive option license agreement with Astellas Pharma Inc. to develop proprietary antagonist antibodies targeting a checkpoint inhibitor pathway in the tumor microenvironment. The partnership includes an upfront payment and potential milestone payments for Twist, while Astellas will handle development and commercialization. This agreement marks a significant step for Twist's Biopharma division, validating its capabilities in antibody discovery and optimization.
Twist Bioscience (NASDAQ: TWST) reported record revenues of $48.1 million for 2QFY22, a 54% increase from the previous year. Orders rose 32% to $55.0 million.
Despite a significant net loss of $60.7 million ($1.13 per share), the company maintained a strong cash position of $604.4 million. New partnerships and expanded product offerings, including a four-year agreement with Ginkgo Bioworks worth $58 million, highlight ongoing growth potential in the synthetic biology and data storage sectors.
Twist Bioscience (NASDAQ: TWST) recently announced six poster presentations at the PEGS Summit in Boston from May 2-6. The presentations focus on the company's advancements in antibody discovery and library construction capabilities, particularly for high-impact targets. Notable sessions include 'Writing the Future of Biologics' by Aaron Sato on May 2 and 'Rapid, Function-Forward mAb Discovery' by Tracey Mullen on May 4. These initiatives aim to enhance the development of therapies like CAR-T cell treatments.
Twist Bioscience Corporation has launched a new High Throughput Antibody Production platform that streamlines the process of generating purified antibodies from digital DNA sequences. This innovation is designed to alleviate bottlenecks in antibody discovery, enhancing efficiency in therapeutic screening. Customers can order antibody sequences through Twist's platform, which employs bioinformatics to filter viable sequences, allowing for the simultaneous production of thousands of distinct antibodies. Deliveries are typically made within 35 business days.
Twist Bioscience Corporation (NASDAQ: TWST) has joined the Storage Networking Industry Association (SNIA) as a voting member. This involvement aims to enhance data protection technology awareness and explore standards for DNA as a long-term data storage medium. SNIA emphasizes the importance of developing vendor-neutral architectures and standards in the storage industry. Twist engages actively to guide the implementation of these new standards, which can potentially impact data storage methods in various sectors, including healthcare and industrial research.
Twist Bioscience (NASDAQ: TWST) has announced the promotion of Tracey Mullen to Senior Vice President of Operations and Nimisha Srivastava to Senior Vice President of Research and Development. This follows the departure of Patrick Weiss from his role as Chief Operating Officer to a strategic advisor position, effective April 21, 2022. Mullen brings extensive experience from her previous role as CEO of Abveris, while Srivastava has been pivotal in automating laboratory processes since joining Twist in 2014. The company continues its growth trajectory in synthetic biology.